| abstract |
The invention relates to a compound having the structure of formula (I), to a process for its preparation and to its use, and to a pharmaceutical composition comprising the compound, wherein R is methyl, ethyl, propyl, vinyl or propenyl. The invention also relates to a crystalline form of the compound, a process for preparing and using the crystalline form, and a pharmaceutical composition comprising the crystalline form. The compound having the structure of formula (I) according to the present invention exists in solid form, which not only solves the problem of resistance to clopidogrel, but can also solve problems relating to the side effects of heavy bleeding and poor safety of some drugs, and can also solve the problem of poor stability of existing compounds, and therefore, the compound can be developed into an antiplatelet drug antagonist of the ADP receptor with obvious efficacy, without any resistance and better stability. (I) |